{"filings":[{"id":95744,"accession_number":"0001818331-26-000039","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).","Exome/genome volume 27,488 (+34% YoY); adjusted gross margin 69% flat YoY.","GAAP net loss $63.3M; adjusted net loss $8.2M vs adjusted net income $9.2M in Q1 2025.","Full-year 2026 revenue guidance $475-$490M with at least 30% exome/genome volume growth; cash $171.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":102254000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109031,"accession_number":"0001818331-26-000021","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"GeneDx enters $100M term loan with Blackstone to repay existing credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M term loan funded Feb 27, 2026; proceeds used to repay existing Perceptive Credit term loan.","Interest rate at Term SOFR + 4.50% (1.50% floor); matures in five years.","Mandatory prepayment triggers include change of control, additional debt, asset sales.","Secured by first lien on substantially all assets; includes $50M minimum liquidity covenant.","Proceeds also for balance sheet optimization and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109030,"accession_number":"0001818331-26-000014","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).","Q4 exome/genome volume 27,761 (+34.3% YoY); adjusted gross margin 71%.","FY2025 revenue $427.5M (+41%); adjusted net income $41.8M vs $9.4M prior year.","Reaffirmed FY2026 revenue guidance $540-555M with 33-35% exome/genome volume growth.","Cash $172.3M; Q4 operating cash flow $5.1M; issued 147,583 shares via ATM netting $21.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":427539000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109029,"accession_number":"0001818331-26-000005","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).","Exome/genome volume 97,271 (+30.5%) for FY2025; Q4 volume up 34.3%.","Adjusted gross margin 71% in Q4 and FY2025; cash & equivalents $172M.","FY2026 guidance: rev $540-555M, 33-35% exome/genome growth, adj gross margin ≥70%.","Expects positive adjusted net income in FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":427539000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125484,"accession_number":"0001818331-25-000128","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).","Adjusted gross margin expanded to 74% from 64%; adjusted net income $14.7M vs $2.0M.","Raised FY2025 revenue guidance to $425-428M; exome/genome growth 53-55% YoY.","Granted FDA Breakthrough Device Designation for ExomeDx and GenomeDx tests."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":306550000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142226,"accession_number":"0001818331-25-000121","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.","Dr. Fuchs serves as SVP and Chief AI Officer at Eli Lilly, leading AI for drug discovery and clinical trials.","Initial RSU grant of $420,000 vesting over three years under non-employee director compensation policy.","Dr. Fuchs holds a doctorate in machine learning from ETH Zurich and founded Paige AI.","No transactions requiring disclosure under Item 404(a) and no arrangements with any person."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142225,"accession_number":"0001818331-25-000105","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).","Adjusted net income $15.0M vs. loss of $2.0M a year ago; GAAP net income $10.8M.","Adjusted gross margin expanded to 71% from 62% in Q2 2024.","Acquired Fabric Genomics for $33.2M in cash, net of cash acquired.","AAP now recommends exome/genome as first-line test for children with global developmental delay."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":189807000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160231,"accession_number":"0001818331-25-000086","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"GeneDx re-elects Casdin and Ruch as Class I directors; EY ratified as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eli D. Casdin re-elected with 16,013,641 votes for, 6,823,343 withheld.","Joshua Ruch re-elected with 17,211,360 votes for, 5,625,624 withheld.","Ratification of Ernst & Young as auditor approved: 25,459,253 for, 49,423 against, 10,809 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160230,"accession_number":"0001818331-25-000070","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 revenue $87.1M, exome/genome revenue up 62% YoY; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 exome/genome revenue $71.4M (+62% YoY); total revenue $87.1M (+42% YoY).","Adjusted net income $7.7M vs loss of $8.0M a year ago; GAAP net loss $6.5M.","Announced plans to acquire Fabric Genomics; no deal value disclosed.","Raised FY 2025 revenue guidance to $360-375M; reaffirms exome/genome growth of at least 30%.","Adjusted gross margin improved to 69% from 61% YoY; cash $160.2M at quarter-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":87115000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160229,"accession_number":"0001818331-25-000057","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeneDx to acquire Fabric Genomics for up to $51M; expands AI genomic interpretation globally","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["GeneDx will pay $33M cash at closing for Fabric Genomics; total consideration up to $51M based on milestone achievements (2025/2026 revenue and margin targets).","Milestone payments of up to $10.5M and $7.5M can be in cash, stock (valued at $93.0318/sh), or combination.","Acquisition expected to close in Q2 2025; Fabric Genomics to operate independently post-close.","Deal enables decentralized sequencing with centralized AI interpretation, expanding NICU, newborn screening, and global markets.","GeneDx's dataset of 750K+ exomes/genomes combined with Fabric's AI platform creates barrier to entry and recurring revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178529,"accession_number":"0001818331-25-000013","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).","Q4 adjusted gross margin 70% (vs 56% YoY); exome/genome margin >70%.","Q4 adjusted net income $16.8M (GAAP net income $5.4M); full year adjusted net income $6.7M.","FY2025 guidance: revenue $350M-$360M, exome/genome volume and revenue growth at least 30%.","Cash $142.2M at year-end; Q4 operating cash flow $12.4M including $6.8M appeal recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":305450000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178528,"accession_number":"0001818331-25-000004","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.","Q4 2024 revenue at least $92M (+59% YoY, +20% sequential); exome/genome rev $75.8M (+93% YoY).","Adjusted gross margin ≥64% FY (guidance ≥62%) and ≥68% in Q4 (up from 64% Q3).","Q4 exome/genome volume 20,676 (+32% YoY, +7% seq); expects second consecutive adjusted net income quarter and first positive operating cash flow.","Includes $6.8M discrete benefit from multi-year appeal recovery from a single payer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":305450000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178527,"accession_number":"0001818331-25-000002","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GeneDx appoints Bryan Dechairo as COO with $450K salary and $2.7M RSU award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan Dechairo appointed COO effective Jan 2, 2025; reports to CEO Katherine Stueland.","Total annual base salary of $450,000 plus target annual bonus of 50% of base salary.","RSUs with $2.7M grant-date value vesting over 4 years; sign-on bonuses of $75K each in 2025 and 2026.","Dechairo previously CEO of Sherlock Biosciences; will oversee Product & Technology, Operations, Medical Affairs, Innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195202,"accession_number":"0001818331-24-000057","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).","Adjusted net income $1.2M (first profitable quarter); GAAP net loss $8.3M.","Adjusted gross margin 64%, up from 48% YoY.","FY 2024 revenue guidance raised to $284–290M (prev. $255–265M).","Cash use improved 88% YoY to $5.0M; $117.4M cash as of Sept. 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":209810000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211463,"accession_number":"0001818331-24-000041","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).","Adjusted gross margin from continuing ops 62% (up from 37% YoY).","Adjusted net loss narrowed to $2.7M, an improvement of 93% YoY.","GAAP net loss $29.2M including $13M one-time litigation charge.","Raises FY2024 revenue guidance to $255-265M; reiterates path to profitability in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":132936000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230109,"accession_number":"0001818331-24-000036","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"GeneDx stockholders elect three Class III directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Emily Leproust, Keith Meister, and Richard Pfenniger Jr. elected as Class III directors with over 17M votes for each.","Auditor ratification: 23,359,773 votes for, 7,938 against, 4,319 abstentions.","All proposals on the ballot were approved at the June 20, 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230108,"accession_number":"0001818331-24-000031","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GeneDx enters $75M at-the-market equity offering agreement with TD Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $75M of Class A common stock through TD Cowen as agent.","TD Cowen will receive up to 3.0% selling commission on gross proceeds.","ATM offering terminates upon sale of all shares or termination of agreement.","Offering made under existing shelf registration statement (File No. 333-267112)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230107,"accession_number":"0001818331-24-000021","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).","Adjusted gross margin expanded to 61% from 34% YoY; exome/genome margin above 65%.","Adjusted net loss narrowed to $8.5M (83% YoY improvement); GAAP net loss $20.2M.","Cash burn reduced 71% YoY to $17.2M; cash position $113.9M as of March 31.","Raised FY 2024 revenue guidance to $235-245M; reiterate path to profitability in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":62422000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}